We have applied for listing of our common stock on The NASDAQ Global Market under the symbol "MACK."Per shareTotalInitial public offering price$$Underwriting discounts and commissions$$Proceeds to Merrimack, before expenses$$We have granted the underwriters an option for a period of 30 days to purchase up to 2,500,000 additional shares of common stock.Investing in our common stock involves a high degree of risk.
significant delays in doing so, we may not receive marketing approval for or realize the full commercial potential of our therapeutics.•We may depend on collaborations with third parties for the development and commercialization of our product candidates.
source has verified such research or estimates.6Table of ContentsThe offeringCommon stock offered by us16,666,667 sharesCommon stock to be outstanding after this offering94,756,679 sharesOver-allotment optionThe underwriters have an option for a period of 30 days to purchase up to 2,500,000 additional shares of our common stock to cover over-allotments.Use of proceedsWe will use approximately $4.3 million of the net proceeds from this offering to pay accrued dividends on our series B convertible preferred stock.We expect to use the balance of the net proceeds from this offering to fund the clinical development of our most advanced product candidates, including MM-398, MM-111, MM-302 and MM-151, to fund
See "Use of proceeds."Sanofi is responsible for all development and manufacturing costs under our collaboration for the development and commercialization of MM-121.Risk factorsYou should read the "Risk factors" section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.Proposed NASDAQ Global Market symbolMACKThe number of shares of our common stock to be outstanding after this offering is based on 11,834,483 actual shares of our common stock outstanding as of
We anticipate that our expenses will increase substantially as we:•initiate or continue our clinical trials of our five most advanced product candidates;•continue the research and development of our other product candidates;•seek to discover additional product candidates;•seek regulatory approvals for our product candidates that successfully complete clinical trials;•establish a sales, marketing and distribution infrastructure and scale up manufacturing capabilities to commercialize
unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or commercialization efforts.We expect that the net proceeds from this offering, together with our existing cash and cash equivalents, anticipated interest income and anticipated milestone payments and research and
Our future capital requirements will depend on many factors, including:•the progress and results of the clinical trials of our five most advanced product candidates;•the success of our collaborations with Sanofi related to MM-121 and PharmaEngine, Inc., or PharmaEngine,
If we are unable to commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.We have invested a significant portion of our efforts and financial resources in the acquisition of rights to MM-398 and the development
the following:•successful enrollment in, and completion of, preclinical studies and clinical trials;•receipt of marketing approvals from the FDA and similar regulatory authorities outside the United States for our product
may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize our product candidates,
may:•be delayed in obtaining marketing approval for our product candidates;•not obtain marketing approval at all;•obtain approval for indications that are not as broad as intended;•have the product removed from the market after obtaining marketing approval;•be subject to additional post-marketing testing requirements; or•be subject to restrictions on how the product is distributed or used.In particular, it is possible that the FDA may not consider the results of our Phase 3 clinical trial of MM-398 for the treatment of patients with metastatic pancreatic cancer, once
are unexpected, we may need to abandon their development.If we experience delays in the enrollment of patients in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of
delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of the company to decline and limit our ability to obtain
The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:•the prevalence and severity of any side effects;•efficacy and potential advantages compared to alternative treatments;•the price we charge for our product candidates;•convenience and ease of administration compared to alternative treatments;•the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;•our ability to successfully develop companion diagnostics that effectively identify patient populations likely to benefit
Our failure to obtain a license to these patents could delay or prevent our development and commercialization of our product candidates in the United States.We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or
forward-looking statements in this prospectus include, among other things, statements about:•our plans to develop and commercialize our most advanced product candidates and companion diagnostics;•our ongoing and planned discovery programs, preclinical studies and clinical trials;•our collaboration with Sanofi related to MM-121;•our ability to establish and maintain additional collaborations;•the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;•the rate and degree of market acceptance and clinical utility of our products;•our intellectual property position;•our commercialization, marketing and manufacturing capabilities and strategy;•the potential advantages of our Network Biology approach to drug research and development;•the potential use of our Network Biology approach in fields other than oncology; and•our estimates regarding expenses, future revenues, capital requirements and needs for additional financing.We
data for the various compounds under development;•the composition of, and changes to, our management team and board of directors;•the lack of liquidity of our common stock as a private company;•the material risks related to our business;•achievement of enterprise milestones, including results of clinical trials and entering into collaboration and license
anticipated level of future funding necessary to initiate multiple Phase 2/3 clinical trials for two or more of these development programs simultaneously.73Table of ContentsThe future values of our common stock in the IPO scenarios and the trade sale scenarios were estimated by application of the market approach based on certain key assumptions,